According to the provided sources, there are no reported birth defects associated with the use of Cosentyx (secukinumab), a biologic drug used to treat psoriasis and psoriatic arthritis.

The first source, Drug Patent Watch [1], provides information on the patent status and regulatory history of Cosentyx, but does not mention any reported birth defects.

The second source, a study published in the Journal of the European Academy of Dermatology and Venereology [2], evaluated the safety and efficacy of Cosentyx in treating psoriasis. The study found that Cosentyx was generally well-tolerated, with no significant safety concerns reported. However, the study did not specifically address the issue of birth defects.

The third source, a review article published in the British Journal of Dermatology [3], also discussed the safety and efficacy of Cosentyx in treating psoriasis. The article noted that there have been no reports of fetal harm or birth defects associated with the use of Cosentyx during pregnancy. However, the article also cautioned that more data is needed to fully understand the potential risks of using Cosentyx during pregnancy.

In conclusion, while there is limited information available on the use of Cosentyx during pregnancy, there are no reported birth defects associated with the drug. However, as with any medication, pregnant women should consult with their healthcare provider before using Cosentyx to ensure that the benefits outweigh any potential risks.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.sciencedirect.com/science/article/pii/S2352647516300375
[3] https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.16901